Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas

Virchows Archiv

Volumn 448, Issue 3, 2006, Pages 331-336

  Choi, Yoon La ^a   Kang, So Young ^a   Shin, Young Kee ^b   Choi, Jong Sun ^a   Kim, Seok Hyung ^c   Lee, Sun Joo ^a   Bae, Duk Soo ^a   Ahn, Geunghwan ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c Chungbuk National University College of Medicine   (South Korea)

Author keywords

Borderline; Methylation; Ovarian tumor; RASSF1; Tumor suppressor gene

Indexed keywords

MOLECULAR MARKER; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

ADULT; AGED; ARTICLE; CANCER INVASION; CHROMOSOME 3P; CLEAR CELL CARCINOMA; CONTROLLED STUDY; CYSTADENOMA; DNA METHYLATION; EARLY DIAGNOSIS; FEMALE; GENE INACTIVATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MICRODISSECTION; MIXED MULLERIAN TUMOR; OVARY ADENOCARCINOMA; OVARY CARCINOMA; OVARY TUMOR; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RASSF1A GENE; SOLID TUMOR; TRANSITIONAL CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ADENOMA; ADULT; DNA METHYLATION; DNA, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PROMOTER REGIONS (GENETICS); TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 33644822879     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00428-005-0091-3     Document Type: Article

References (21)

1. Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Rader J, Fullwood P, Chauhan A, Walker R, Shaw JA, Hosoe S, Lerman MI, Minna JD, Maher ER, Latif F (2001) Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene 20:1509-1518
2. Bell DA, Weinstock MA, Scully RE (1988) Peritoneal implants of ovarian serous borderline tumors. Histologic features and prognosis. Cancer 62:2212-2222
3. Bell KA, Smith Sehdev AE, Kurman RJ (2001) Refined diagnostic criteria for implants associated with ovarian atypical proliferative serous tumors (borderline) and micropapillary serous carcinomas. Am J Surg Pathol 25:419-432
4. Dammann R, Yang G, Pfeifer PF (2001) Hypermethylation of the CpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res 61:3105-3109
5. de Nictolis M, Montironi R, Tommasoni S, Carinelli S, Ojeda B, Matias-Guiu X, Prat J (1992) Serous borderline tumors of the ovary. A clinicopathologic, immunohistochemical, and quantitative study of 44 cases. Cancer 70:152-160
6. Ford D, Easton D (1995) The genetics of breast and ovarian cancer. Br J Cancer 72:805-812
7. Fullwood P, Marchini S, Rader JS, Martinez A, Macartney D, Broggini M, Morelli C, Barbanti-Brodano G, Maher ER, Latif F (1999) Detailed genetic and physical mapping of tumor suppressor loci on chromosome 3p in ovarian cancer. Cancer Res 59:4662-4667
8. Honorio S, Agathanggelou A, Schuermann M, Pankow W, Viacava P, Maher ER, Latif F (2003) Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients. Oncogene 22:147-150
9. Ibanez de Caceres I, Battagli C, Esteller M, Herman JG, Dulaimi E, Edelson MI, Bergman C, Ehya H, Eisenberg BL, Cairns P (2004) Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res 64:6476-6481
10. Lee JY, Dong SM, Kim SY, Yoo NJ, Lee SH, Park WS (1998) A simple, precise and economical microdissection technique for analysis of genomic DNA from archival tissue sections. Virchows Arch 433:305-309
11. Lee MG, Kim HY, Byun DS, Lee SJ, Lee CH, Kim JI, Chang SG, Chi SG (2001) Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. Cancer Res 61:6688-6692
12. Murdoch WJ (1996) Ovarian surface epithelium, ovulation and carcinogenesis. Biol Rev Camb Philos Soc 71:529-543
13. NIH consensus conference (1995) Ovarian cancer. Screening, treatment and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA 273:491-497
14. Rathi A, Virmani AK, Schorge JO, Elias KJ, Maruyama R, Minna JD, Mok SC, Girard L, Fishman DA, Gazdar AF (2002) Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin Cancer Res 8:3324-3331
15. Rimessi P, Gualandi F, Morelli C, Trabanell C, Wu Q, Possati L, Montesi M, Barrett JC, Barbanti-Brodano G (1994) Transfer of human chromosome 3 to an ovarian carcinoma cell line identifies three regions on 3p involved in ovarian cancer. Oncogene 9:3467-3474
16. Russell SE, McCluggage WG (2004) A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes. J Pathol 203:617-619
17. Silva EG, Kurman RJ, Russell P, Scully RE (1996) Symposium: ovarian tumors of borderline malignancy. Int J Gynecol Pathol 15:281-302
18. Song MS, Song SJ, Ayad NG, Chang JS, Lee JH, Hong HK, Lee H, Choi N, Kim J, Kim H, Kim JW, Choi EJ, Kirschner MW, Lim DS (2004) The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex. Nat Cell Biol 6:129-137
19. Wong IH, Chan J, Wong J, Tam PK (2004) Ubiquitous aberrant RASSF1A promoter methylation in childhood neoplasia. Clin Cancer Res 10:994-1002
20. Xing M Cohen Y, Mambo E, Tallini G, Udelsman R, Ladenson PW, Sidransky D (2004) Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. Cancer Res 64:1664-1668
21. Yoon JH, Dammann R, Pfeifer GP (2001) Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas. Int J Cancer 94:212-217